These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10480438)

  • 1. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
    Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
    Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.
    Jalanko A; Tenhunen K; McKinney CE; LaMarca ME; Rapola J; Autti T; Joensuu R; Manninen T; Sipilä I; Ikonen S; Riekkinen P; Ginns EI; Peltonen L
    Hum Mol Genet; 1998 Feb; 7(2):265-72. PubMed ID: 9425233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
    Virta S; Rapola J; Jalanko A; Laine M
    J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.
    Laitinen A; Hietala M; Haworth JC; Schroeder ML; Seargeant LE; Greenberg CR; Aula P
    Clin Genet; 1997 Mar; 51(3):174-8. PubMed ID: 9137882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive neurodegeneration in aspartylglycosaminuria mice.
    Gonzalez-Gomez I; Mononen I; Heisterkamp N; Groffen J; Kaartinen V
    Am J Pathol; 1998 Oct; 153(4):1293-300. PubMed ID: 9777961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
    Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
    J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
    Enomaa N; Danos O; Peltonen L; Jalanko A
    Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model for the human lysosomal disease aspartylglycosaminuria.
    Kaartinen V; Mononen I; Voncken JW; Noronkoski T; Gonzalez-Gomez I; Heisterkamp N; Groffen J
    Nat Med; 1996 Dec; 2(12):1375-8. PubMed ID: 8946839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the CNS pathology in aspartylglucosaminuria mice.
    Tenhunen K; Uusitalo A; Autti T; Joensuu R; Kettunen M; Kauppinen RA; Ikonen S; LaMarca ME; Haltia M; Ginns EI; Jalanko A; Peltonen L
    J Neuropathol Exp Neurol; 1998 Dec; 57(12):1154-63. PubMed ID: 9862638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
    Ikonen E; Peltonen L
    Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.
    Dunder U; Valtonen P; Kelo E; Mononen I
    J Inherit Metab Dis; 2010 Oct; 33(5):611-7. PubMed ID: 20607610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A family with two children diagnosed with aspartylglucosaminuria-case report and literature review].
    Liu Y; Zou L; Meng Y; Zhang Y; Shi X; Ju J; Yang G; Hu L; Chen X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):455-9. PubMed ID: 25190167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
    Saarela J; von Schantz C; Peltonen L; Jalanko A
    Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients.
    Enomaa NE; Lukinmaa PL; Ikonen EM; Waltimo JC; Palotie A; Paetau AE; Peltonen L
    J Histochem Cytochem; 1993 Jul; 41(7):981-9. PubMed ID: 7685790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.
    Dunder U; Kaartinen V; Valtonen P; Väänänen E; Kosma VM; Heisterkamp N; Groffen J; Mononen I
    FASEB J; 2000 Feb; 14(2):361-7. PubMed ID: 10657992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
    Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
    Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartylglycosaminuria: biochemistry and molecular biology.
    Aronson NN
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):139-54. PubMed ID: 10571008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.